

# Parkinson Association Of

Executive Director / CEO

EIN 300064156

NC · NTEE H20

FY ending 2024-06-30

June 9, 2026

This analysis benchmarks the total compensation of **Ann Marie Worman, Executive Director / CEO** (\$78,138) against **every comparable organization** that fit the selection criteria — **152** in total — drawn systematically from IRS Form 990 filings, not a hand-picked subset.

Compensation sits at approximately the **56<sup>th</sup>** percentile of comparable organizations within the typical range


**Benchmarked executive:** Ann Marie Worman — reported title “Executive Dir.,” a **direct title match** to the Executive Director / CEO role.

## How comparable organizations were selected

SECTOR	Organizations sharing the subject's NTEE classification (H20).
BUDGET	Total revenue between \$323,033 and \$723,210 — 0.67x to 1.50x the subject's \$482,140 (the band tightens as size grows).
GEOGRAPHY	Same NTEE major group (H), nationwide + budget 0.67–1.5x revenue.

**152** organizations qualified on sector, size, and geography → **152** within the band form the benchmarked peer set.

## Distribution of comparable compensation



\$24,177	\$42,217	\$71,205	\$108,313	\$166,419	<b>\$78,138</b>
----------	----------	----------	-----------	-----------	-----------------



## ● Comparable organizations

Each figure is Form 990 Part VII columns D + F (reportable pay plus other compensation and benefits; column F may include amounts from related organizations), normalized to NC cost of living (BEA RPP, 2023) and to its filing year (CPI-U); the reported amount is on each linked 990.

ORGANIZATION	STATE	REVENUE	MATCHED TITLE	COMP (REPORTED)	COMP (ADJUSTED)	FY
<a href="#">Odylia Therapeutics Inc</a>	GA	\$482,047	Ceo/cso	\$225,220	<b>\$219,164</b>	2024
<a href="#">American Cochlear Implant Alliance</a>	VA	\$483,427	Executive Director	\$201,375	<b>\$188,177</b>	2024
<a href="#">St Louis Life Sciences Project</a>	MO	\$479,877	President/secretary/treasu	\$201,834	<b>\$213,002</b>	2023
<a href="#">American Board Of Medical Specialties</a>	IL	\$484,417	President & Ceo	\$114,596	<b>\$112,255</b>	2023
<a href="#">Global Vitiligo Foundation</a>	PA	\$478,511	Executive Director	\$83,694	<b>\$83,161</b>	2023
<a href="#">Autism Tree Project Inc</a>	CA	\$477,889	Executive Dir.	\$90,000	<b>\$75,213</b>	2024
<a href="#">Central New York Lyme And</a>	NY	\$486,936	Executive Director	\$107,120	<b>\$93,680</b>	2024
<a href="#">Tom Slick Memorial Trust For Sw</a>	TX	\$487,198	President & Ceo	\$65,374	<b>\$65,158</b>	2023
<a href="#">North Carolina Association For</a>	NC	\$487,929	President	\$145,846	<b>\$145,846</b>	2024
<a href="#">Knox Martin Foundation</a>	GA	\$488,266	President/ce	\$90,000	<b>\$90,167</b>	2023
<a href="#">Cancollaborate Inc</a>	MA	\$471,902	President	\$52,083	<b>\$46,633</b>	2023
<a href="#">Jayden Deluca Foundation Inc</a>	ID	\$492,957	Executive Director	\$28,300	<b>\$29,997</b>	2023
<a href="#">Mycoses Study Group Education And</a>	AL	\$470,737	Executive Director (Non-vo	\$26,400	<b>\$27,603</b>	2024
<a href="#">Veterans Research &amp; Education</a>	OK	\$493,862	Executive Di	\$51,364	<b>\$54,738</b>	2024

ORGANIZATION	STATE	REVENUE	MATCHED TITLE	COMP (REPORTED)	COMP (ADJUSTED)	FY
<a href="#">The Myocarditis Foundation</a>	TX	\$468,356	Executive Director	\$107,000	<b>\$103,587</b>	2024
<a href="#">Dorn Research Institute Inc</a>	SC	\$460,393	Executive Di	\$125,000	<b>\$126,207</b>	2024
<a href="#">Minneapolis Radiology And Vascular</a>	MN	\$504,944	President	\$8,034	<b>\$7,683</b>	2024
<a href="#">Genetic Information Research Institute</a>	CA	\$506,275	Trustee	\$129,149	<b>\$107,930</b>	2024
<a href="#">Massachusetts Society For</a>	MA	\$457,668	President	\$121,978	<b>\$109,216</b>	2023
<a href="#">American Society For Metabolic And</a>	FL	\$455,062	Dir/exec Dir '24	\$47,782	<b>\$43,442</b>	2024
<a href="#">Academy For Health &amp; Lifespan</a>	NY	\$454,339	Executive Dir.	\$60,927	<b>\$54,857</b>	2023
<a href="#">Minkoff Center For Jewish Genetics</a>	AZ	\$453,924	Executive Director	\$132,870	<b>\$123,670</b>	2024
<a href="#">Neurofibromatosis Network</a>	IL	\$452,414	Executive Di	\$104,158	<b>\$99,103</b>	2024
<a href="#">Behavioral Diabetes Institute</a>	CA	\$450,812	Director	\$222,395	<b>\$185,856</b>	2024
<a href="#">New Jersey Institute For Medical</a>	NJ	\$513,625	Chairman	\$93,000	<b>\$80,361</b>	2024

**Comp (reported)** is the figure on each organization's Form 990 (columns D + F); **Comp (adjusted)** normalizes it to NC cost of living and 2024 dollars. Click any organization to verify the figure on ProPublica.

## ● Methodology

Comparable organizations were drawn from electronically filed IRS Form 990 returns and matched on sector (NTEE code), budget (a size-adaptive revenue band that tightens as the organization grows), and geography (same-state first, broadening only when too few peers qualify); every organization within the band forms the peer set. To compare fairly across regions and years, peer compensation is normalized to NC cost of living (BEA Regional Price Parities, 2023) and to the subject's filing year (CPI-U). The figure benchmarked is Form 990 Part VII, Section A, columns D + F — reportable pay plus other compensation, benefits, and deferred amounts (column F may include amounts from related organizations) — with the chief executive matched by role. Related-organization amounts (column E) and institutional trustees are excluded. Full methodology: [peerbasis.org/methodology](https://peerbasis.org/methodology).

## ■ Sample, role match & sensitivity

PEER COUNT	152 organizations. Compensation range \$414–\$459,481; filing years 2023–2025.
SIZE BASIS	Matched on total revenue (\$482,140); for reference, expenses \$403,573 and assets \$2,077,652.
ROLE MATCH	Ann Marie Worman, reported title " <i>Executive Dir.</i> ", benchmarked as Executive Director / CEO. The title maps directly to this role.
RELATED-ORG PAY	19 peers report related-organization compensation (column E), which the D + F benchmark does not fully capture; review where material.
OUTLIERS	9 peers fall outside 1.5× the interquartile range — consider whether any reflect one-time payments (severance, deferred-comp payouts).

Sensitivity — the subject's percentile under alternative compensation definitions:

BASIS	SUBJECT PERCENTILE
Total compensation (D + F), cost-of-living + inflation adjusted — the PeerBasis default	56 <sup>th</sup>
Total compensation (D + F), as reported (no adjustments)	53 <sup>rd</sup>
Reportable pay only (column D), adjusted	59 <sup>th</sup>
All sources (D + E + F), adjusted	47 <sup>th</sup>

If the percentile moves materially across these definitions, the result is sensitive to methodology choices, and the board should weigh which basis best fits its facts.

## ■ Rebuttable presumption of reasonableness · 26 CFR 53.4958-6

Compensation paid by a tax-exempt organization is presumed reasonable — shifting the burden to the IRS — when three requirements are met. This report supplies the comparability data for the second. The board should record the following in its minutes *concurrently* with its decision:

### Draft board minutes – executive compensation

1. The compensation of the Executive Director / CEO (Ann Marie Worman) was approved in advance by [the Board / Compensation Committee], composed of members with no conflict of interest with respect to the arrangement.
2. Prior to its determination, the authorized body obtained and relied upon appropriate comparability data, namely the PeerBasis Compensation Comparability Determination dated June 9, 2026, comparing compensation against 152 similarly situated organizations (Same NTEE major group (H), nationwide + budget 0.67–1.5× revenue).
3. The authorized body determined that total compensation of \$78,138 is reasonable (approximately the 56<sup>th</sup> percentile of comparable organizations) and documented the basis for this determination

concurrently, on [date], by a vote of [\_\_ for / \_\_ against].

---

Sources: IRS Form 990 e-file data (apps.irs.gov); IRS Business Master File (NTEE classification). Every figure traces to an original public filing — click any organization above to verify it on ProPublica. PeerBasis is a service of Prismind Analytics; its [methodology is published](#), was commissioned for independent adversarial review, and discloses its own limitations. This report is comparability data to support a board's good-faith determination under IRC 4958; it is not legal or tax advice. Generated by PeerBasis on June 9, 2026.